Back

Neurohormonal status is associated with long-term appropriate implantable cardioverter defibrillator therapy for life-threatening ventricular arrhythmia

27 August 2023 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Risk stratification, devices, and ablation in the management of malignant ventricular arrhythmias Cardioversion and Defibrillation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Farzin Beygui

University Hospital of Caen, Caen (France)

7 More presentations in this session

Presentation thumbnail
Catheter ablation for ventricular tachycardia after myocardial infarction: meta-analysis of randomised controlled trials
Doctor R. Reddy (Durham, US)
Abstract Slides Video
Presentation thumbnail
Influence of standard modifiable risk factors on ventricular tachycardia after myocardial infarction
Doctor T. Deshmukh (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Surpoint algorithm for improved guidance of ablation for ventricular tachycardia (SURFIRE-VT): a propensity-matched study
Doctor D. Sanders (Chicago, US)
Abstract Slides Video
Presentation thumbnail
Association of ventricular tachycardia morphology induced on electrophysiology study after myocardial infarction: long-term survival and ventricular tachyarrhythmia recurrence
Doctor J. Kovoor (Westmead, AU)
Abstract Slides Video
Presentation thumbnail
Sex-differences in ventricular tachyarrhythmia events in patients with implantable cardioverter defibrillator and prior ventricular tachyarrhythmias
Doctor B. Krzowski (Warsaw, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification, devices, and ablation in the management of malignant ventricular arrhythmias

The Event

Event poster

ESC Congress 2023

27 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Marked differences in ICD therapy frequencies between phenotypes
thumbnail
Congress Presentation
Long-term follow-up in patients with hypertrophic cardiomyopathy after defibrillator implantation: analysis of appropriate and inappropriate therapy
thumbnail
Congress Presentation
Primary prevention implantable cardioverter defibrillators are no longer indicated in non-ischaemic HFrEF: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources